On October 20, Kodiak Sciences Inc. rose 6.27% in Regular Trading, trading at $91.135/share, with turnover of $23.2711 million.
The main public catalyst in focus remains the company’s late-September disclosure that Zenkuda and tabirafusp-ted met primary endpoints in a Phase 3 wet AMD study, followed by director Felix Baker’s roughly $157 million share purchase through Baker Bros. Advisors.
Earlier disclosures said both drug candidates achieved non-inferiority in vision gains versus aflibercept in the first year, with 54% of patients maintaining a six-month dosing interval, and the company plans to submit Zenkuda data from five positive Phase 3 studies to regulators in the fourth quarter. Separately, Baker’s purchase was described as his largest to date, executed at about $80.85 per share, lifting the affiliated firm’s stake to about 35%, reinforcing market attention on the stock after its sharp post-data re-rating.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments